Maryland Caps Payments on Jardiance and Ozempic
State and local government health plans in Maryland will face new payment limits on these diabetes drugs beginning January 1, 2027.
Updated on Nov. 17, 2026 in Health

Live Poll
Do you think government limits on prescription drug prices will lower what you pay?
Maryland's Prescription Drug Affordability Board unanimously approved the first upper payment limits on prescription drugs in the nation, covering the diabetes and weight-management medicines Jardiance and Ozempic. The limits are scheduled to take effect January 1, 2027, and are projected to primarily benefit government health plans rather than individual patients.
Why it matters
The limits aim to reduce what state and local governments pay for certain high-cost prescriptions, which matters for public employee coverage and the budgets that fund it. Because most participating plans already charge flat copays, the savings are expected to flow mainly to plans instead of lowering what patients pay at the pharmacy.
The figure comes from the Maryland Prescription Drug Affordability Board's own projection, calculated from estimated net costs after discounts and rebates for the two drugs. It is a forecast made before the limits take effect, so actual savings will depend on how participating plans' spending changes.
The players
Maryland Prescription Drug Affordability Board
A Maryland state body created in 2019 to review prescription drug costs and set upper payment limits for state and local government health plans.
Boehringer Ingelheim
A pharmaceutical company that manufactures Jardiance, a diabetes medication used to manage blood sugar and related heart and kidney outcomes.
Novo Nordisk
A pharmaceutical company that manufactures Ozempic, a GLP-1 medication used to treat type 2 diabetes and widely prescribed for weight management.
The details
Under the regulations, health plans that participate will receive supplemental rebates whenever their net spending on Jardiance or Ozempic exceeds the state-set limit. That structure means the state sets a ceiling on what it considers acceptable net cost, and plans are compensated when costs run above it. Participation is voluntary for eligible state and local government entities during the first year, and becomes mandatory for entities that opt in beginning January 1, 2028. The limits do not apply to Wegovy.
Timeline
2019: Maryland created its prescription drug affordability board.
November 16, 2026: The board voted unanimously to approve the Jardiance and Ozempic limits in Baltimore.
January 1, 2027: The upper payment limits take effect and voluntary participation begins.
January 1, 2028: Participation becomes mandatory for entities that opted in.
Health Landscape
Maryland's limits are the first upper payment limits on prescription drugs anywhere in the nation, placing the state at the front of a cost-control approach for widely used diabetes and weight-management medicines. The move targets government plans specifically, a different lever than the patient-cost reductions that often dominate national drug-pricing debate.
If you receive coverage through a Maryland state or local government health plan, the limits may influence the drugs your plan can afford to cover, though patient copays are not expected to change much. Anyone taking Jardiance, Ozempic, or a related diabetes medication should keep discussing coverage and treatment options with their physician rather than changing anything based on this news.
The takeaway
Maryland's approach shows that state governments can set enforceable limits on the cost of widely prescribed diabetes medicines, with savings aimed at public health plans. Anyone with questions about how coverage changes could affect their prescriptions should raise them with their doctor or plan administrator.
Further reading
For broader background on how these diabetes medicines are managed and priced, explore the Diabetes section.
Live Poll
Do you think government limits on prescription drug prices will lower what you pay?




